Glenmark Sets Sights On Regional Out-Licensing, Lot Riding On US Rhinitis NDA

With a basket of interesting R&D assets in hand, India’s Glenmark says it is pursuing regional out-licensing deals, including in Japan and China, for some of its molecules. Expectations are also running high on the firm’s first US NDA submission for seasonal allergic rhinitis.

Success ladder leading to cloud and many short ones. Business, goal, competition, unique, progress, challenge, hope and leadership concept. EPS 8 vector illustration, no transparency
GLENMARK IS KEEN TO MONETIZE SOME OF ITS KEY R&D ASSETS VIA LICENSING

Out-licensing deals this year for some key R&D assets could be critical for Glenmark Pharmaceuticals Ltd. as it concentrates on evolving into a more innovation-led and discovery-driven company from a largely pure generics concern.

Glenmark chair and managing director Glenn Saldanha said that licensing was a key priority for the firm this year and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip